Eton Pharmaceuticals

Contributing Author

Recent Articles by Eton Pharmaceuticals

Aug-27	Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference ETON GlobeNewswire
Aug-13	Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results ETON ETON +44.26% GlobeNewswire
Aug-05	Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 ETON GlobeNewswire
Aug-03	Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 ETON GlobeNewswire
Jul-29	Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI (hydrocortisone) Oral Solution ETON GlobeNewswire
May-19	Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) ETON GlobeNewswire
May-14	Eton Pharmaceuticals Reports First Quarter 2026 Financial Results ETON GlobeNewswire
May-12	Eton Pharmaceuticals to Participate in Upcoming Investor Conferences ETON GlobeNewswire
May-04	Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 ETON GlobeNewswire
May-01	Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution ETON +19.82% GlobeNewswire
Apr-27	Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 ETON GlobeNewswire
Apr-16	Eton Pharmaceuticals Announces CFO Succession Plan ETON -9.42% GlobeNewswire
Mar-19	Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results ETON +9.20% ETON +7.46% GlobeNewswire
Mar-03	Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 ETON GlobeNewswire
Mar-02	Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL (propranolol hydrochloride) Oral Solution ETON +6.83% GlobeNewswire
Feb-25	Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA (desmopressin acetate) Oral Solution ETON GlobeNewswire
Feb-20	Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th ETON GlobeNewswire
Feb-02	Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate ETON GlobeNewswire
Nov-24	Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th ETON GlobeNewswire
Nov-12	Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th ETON GlobeNewswire
Nov-06	Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results ETON ETON -11.70% GlobeNewswire
Oct-23	Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 ETON GlobeNewswire
Aug-20	Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference ETON GlobeNewswire
Aug-07	Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results ETON ETON +12.32% GlobeNewswire
Jul-28	Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 ETON GlobeNewswire
Jul-08	Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) ETON +9.80% GlobeNewswire
Jun-27	Eton Pharmaceuticals Announces Addition to Russell 2000 and Russell 3000 Indexes ETON GlobeNewswire
May-28	Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI (hydrocortisone) Oral Solution ETON ETON -5.78% GlobeNewswire
May-14	Eton Pharmaceuticals to Participate at Upcoming Investor Conferences ETON ETON +15.07% GlobeNewswire
May-13	Eton Pharmaceuticals Reports First Quarter 2025 Financial Results ETON GlobeNewswire
May-01	Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 ETON GlobeNewswire

Eton Pharmaceuticals

Recent Articles by Eton Pharmaceuticals

Upgrade your Finviz experience